Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Net Margin (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Net Margin data on record, last reported at 1093.33% in Q4 2025.

  • For Q4 2025, Net Margin changed N/A year-over-year to 1093.33%; the TTM value through Dec 2025 reached 135.96%, changed N/A, while the annual FY2025 figure was 142.91%, 721791.0% down from the prior year.
  • Net Margin reached 1093.33% in Q4 2025 per RCUS's latest filing, down from 400.0% in the prior quarter.
  • Across five years, Net Margin topped out at 126.03% in Q3 2024 and bottomed at 1093.33% in Q4 2025.
  • Average Net Margin over 5 years is 360.67%, with a median of 259.96% recorded in 2023.
  • The widest YoY moves for Net Margin: up 177268bps in 2021, down -82700bps in 2021.
  • A 5-year view of Net Margin shows it stood at 78.83% in 2021, then tumbled by -353bps to 199.07% in 2022, then tumbled by -31bps to 261.29% in 2023, then surged by 148bps to 126.03% in 2024, then plummeted by -968bps to 1093.33% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 1093.33% in Q4 2025, 400.0% in Q1 2025, and 126.03% in Q3 2024.